WEBULL
WebtradeDownload

Can DuPont De Nemours (DD) Justify Its Price on Cash Flow?

Simply Wall St · 2d ago

DuPont de Nemours has delivered a strong share price run in recent years, so the real issue now is whether the current US$137.67 price can be supported by the cash flows the business is expected to generate. With the stock firmly in focus, investors are increasingly asking if its recent momentum and new product efforts still line up with its intrinsic value based on a Discounted Cash Flow (DCF) view.

  • Over the past 3 years DuPont de Nemours has returned 59.5%, which puts a lot of accumulated optimism on the line when you test the stock against its cash flow profile.
  • The launch of AmberChrom SIL silica gel aimed at peptide therapeutics may support expectations for future cash generation, especially if bioprocessing demand helps the company widen or sustain returns from this part of the portfolio.
  • What if you looked at DuPont de Nemours through its earnings instead? See why DuPont de Nemours's 60.8x P/E tells a different valuation story.

The stock's next move may depend on whether the cash flows implied by a Discounted Cash Flow (DCF) estimate line up with where DuPont de Nemours trades today.

If you are weighing DuPont de Nemours against other opportunities that hinge on cash generation, it can help to line it up beside 29 high quality undervalued stocks.

Is DuPont de Nemours a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model here takes the cash DuPont de Nemours generates and projects it forward, then discounts those streams back to today. Latest twelve month free cash flow sits at about $866.3 million, and the forecast path assumes that this pool of cash grows over time rather than shrinks, with later years still using positive but moderating increases.

That growing cash profile points to an estimated intrinsic value that the DCF suggests is substantially above the current share price of $137.67. Because AmberChrom SIL expands DuPont de Nemours' bioprocessing purification lineup at a time of rising interest in peptide therapeutics, the market may not yet fully reflect the potential cash contribution of this newer product range. The stock therefore screens as supported by a cash flow outlook that is stronger than the price currently implies. Find out what DuPont de Nemours could be worth using our Discounted Cash Flow (DCF) estimate.

The DuPont de Nemours Narrative: What Would Justify Today's Price?

Narratives pick up where the DCF puzzle leaves you by spelling out which future paths for DuPont de Nemours' growth, margins and earnings would need to play out for the stock to look materially cheaper or richer than today's price. They sit on Simply Wall St's Community page, and each one links its number to a specific view on how the business might expand, protect profitability and handle risks, which you can revisit as fresh information comes through.

One of the top community narratives on DuPont de Nemours: 17% undervalued

"Disciplined capital allocation that combines high free cash flow conversion near 100% with sizeable share repurchases, dividends and over US$1b of capacity for Healthcare and Water acquisitions..."

Discover why this Narrative puts DuPont de Nemours at 17% undervalued.

The price of DuPont de Nemours is only one piece of the decision

DCF work and product updates tell only part of the DuPont de Nemours story, since our broader checks have also highlighted potential concerns that careful investors may want to review in detail. Take a closer look at 2 warning signs before settling on a valuation.